An independent two-stage DCF analysis by a frontier AI model.
" data-astro-cid-eotenzz6> Vertex dominates the cystic fibrosis (CF) market, providing highly predictable and growing cash flows. Revenue grew 8.9% in 2025 and ~11% in 2024. FCF has been lumpy due to acquisitions (like the drop in 2024), but underlying operations support a 10% annualized growth rate over the next five years.
" data-astro-cid-eotenzz6> Vertex dominates the cystic fibrosis (CF) market, providing highly predictable and growing cash flows. Revenue grew 8.9% in 2025 and ~11% in 2024. FCF has been lumpy due to acquisitions (like the drop in 2024), but underlying operations support a 10% annualized growth rate over the next five years.
" data-astro-cid-eotenzz6> Vertex dominates the cystic fibrosis (CF) market, providing highly predictable and growing cash flows. Revenue grew 8.9% in 2025 and ~11% in 2024. FCF has been lumpy due to acquisitions (like the drop in 2024), but underlying operations support a 10% annualized growth rate over the next five years.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 8.0% | 8.5% | 9.0% | 9.5% | 10.0% |
|---|---|---|---|---|---|
| 8.0% | $12.00 | $12.00 | $12.00 | $12.00 | $12.00 |
| 8.5% | $12.00 | $12.00 | $12.00 | $12.00 | $12.00 |
| 9.0% | $12.00 | $12.00 | $12.00 | $12.00 | $12.00 |
| 9.5% | $12.00 | $12.00 | $12.00 | $12.00 | $12.00 |
| 10.0% | $12.00 | $12.00 | $12.00 | $12.00 | $12.00 |
■ Undervalued vs current price ■ Overvalued vs current price
Westmount Research. "Vertex Pharmaceuticals (VRTX) Intrinsic Value: A DCF Analysis." westmountfundamentals.com, March 18, 2026.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.